Tumor acidity, ion trapping and chemotherapeutics: I. Acid pH affects the distribution of chemotherapeutic agents in vitro

Biochemical Pharmacology

Volumn 66, Issue 7, 2003, Pages 1207-1218

  Mahoney, Brent P ^a   Raghunand, Natarajan ^a   Baggett, Brenda ^a   Gillies, Robert J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acid base; Chemotherapy; Multidrug resistance; Weak acid; Weak base

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIINFECTIVE AGENT; BREAST CANCER RESISTANCE PROTEIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; MITOXANTRONE; PACLITAXEL; PROTEIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; ION TRANSPORT; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0141786825     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00467-2     Document Type: Article

References (75)

1. Veronesi U., Banfi A., Salvadori B., Luini A., Saccozzi R., Zucali R., Marubini E., Del Vecchio M., Boracchi P., Marchini S. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur. J. Cancer. 26:1990;668-670.
2. Veronesi U., Salvadori B., Luini A., Greco M., Saccozzi R., Del Vecchio M., Mariani L., Zurrida S., Rilke F. Breast conservation is a safe method in patients with small cancer of the breast: long-term results of three randomized trials on 1973 patients. Eur. J. Cancer. 31A:1995;1574-1579.
3. Diab S.G., Hilsenbeck S.G., de Moor C., Clark G.M., Osborne C.K., Ravdin P.M., Elledge R.M. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J. Clin. Oncol. 16:1998;1655-1660.
4. Fisher B., Anderson S., Redmond C.K. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. New Engl. J. Med. 333:1995;1456-1461.
5. Senn H.J., Maibach R., Castiglione M., Jungi W.F., Cavalli F., Leyvraz S., Obrecht J.P., Schildknecht O., Siegenthaler P. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil - 11-year results of Swiss Group for Chinese Cancer Research Trials SAKK 27/82. J. Clin. Oncol. 15:1997;2502-2509.
6. Raghunand N., Martinez-Zaguilan R., Wright S.H., Gillies R.J. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem. Pharmacol. 57:1999;1047-1058.
7. Gillies R.J., Raghunand N., Karczmar G.A., Bhujwalla Z.M. MR Imaging of the tumor microenvironment. J. Magn. Reson. Imaging. 16:2002;430-450.
8. Raghunand N., Gillies R.J. pH and drug resistance in tumors. Drug Resist. Updates. 3:2002;39-47.
9. Wike-Hooley J.L., Haven J., Reinhold H.S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 2:1984;343-366.
10. 31P MR spectroscopy Biochem. Pharmacol. 57:1999;309-312.
11. 31P probes NMR Biomed. 12:1999;495-504.
12. Stubbs M., Rodrigues L., Howe F.A., Wang J., Jeong K.S., Veech R.L., Griffiths J.R. Metabolic consequences of a reversed pH gradient in rat tumours. Cancer Res. 54:1994;4011-4016.
13. 1H MRSI Magn. Reson. Med. 41:1999;743-750.
14. Garcia-Martin M.L., Herigault G., Remy C., Farion R., Ballesteros P., Coles J.A., Cerdan S., Ziegler A. Mapping extracellular pH in rat brain gliomas in vivo by H-1 magnetic resonance spectroscopic imaging: comparison with maps of metabolites. Cancer Res. 61:2001;6524-6531.
15. Bhujwalla Z.M., Artemov D., Ballesteros P., Cerdan S., Gillies R.J., Solaiyappan M. Combined vascular and extracellular pH imaging of solid tumors. NMR Biomed. 15:2002;114-119.
16. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 5:1992;303-324.
17. Newell K., Wood P., Stratford I., Tannock I. Effects of agents which inhibit the regulation of intracellular pH on murine solid tumours. Br. J. Cancer. 66:1992;311-317.
18. Ohtsubo T., Igawa H., Saito T., Matsumoto H., Park H.J., Song C.W., Kano E., Saito H. Acidic environment modifies heat- or radiation-induced apoptosis in human maxillary cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 49:2001;1391-1398.
19. Smalley R.V., Lefante J., Bartolucci A., Carpenter J., Vogel C., Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, vincristine and prednisone (CMFVP) in patients with advanced breast cancer: a southeastern cancer study group project. Breast Cancer Res. Treat. 3:1983;209-220.
20. Taylor C.W., Dalton W.S., Mosley K., Dorr R.T., Salmon S.E. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Res. Treat. 42:1997;7-14.
21. Burghouts J.T. Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity. Neth. J. Med. 36:1990;43-45.
22. Taylor C.W., Dalton W.S., Parrish P.R., Gleason M.C., Bellamy W.T., Thompson F.H., Roe D.J., Trent J.M. Different mechanisms of decreased accumulation in doxorubicin and mitoxantrone resistant variants of the MCF-7 human breast cancer cell line. Br. J. Cancer. 63:1991;923-929.
23. Scheffer G.L., Maliepaard M., Pijnenborg A.C., van Gastelen M.A., de Jong M.C., Schroeijers A.B., van der Kolk D.M., Allen J.D., Ross D.D., van der Valk P., Dalton W.S., Schellens J.H., Scheper R.J. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 60:2000;2589-2593.
24. Arcamone F., Franceschi G., Penco S., Selvia A. Adriamycin 14-hydroxydaunomycin: a novel antitumor antibiotic. Tetrahedron Lett. 13:1969;1007-1016.
25. Harris P.A., Gross J.F. Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Ther. Rep. 59:1975;819-825.
26. Painter R.B. Inhibition of DNA replicon initiation by 4-nitroquinoline-1-oxide, adriamycin, and ethyleneimine. Cancer Res. 38:1978;4445-4449.
27. Kim S.H., Kim J.H. Lethal effect of adriamycin on the division of HeLa cells. Cancer Res. 32:1972;323-325.
28. Gieseler F., Glasmacher A., Kampfe D., Wandt H., Nuessler V., Valsamas S., Kunze J., Wilms K. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxins. Leukemia. 10:1996;1177-1180.
29. Moriyama Y., Manabe T., Yoshimori T., Tashiro Y., Futai M. ATP-dependent uptake of anti-neoplastic agents by acidic organelles. J. Biochem. 115:1994;213-218.
30. +-ATPase in drug-resistant human breast carcinoma cell lines. Biochem. Pharmacol. 57:1999;1037-1046.
31. Dubowchik G.M., Padilla L., Edinger K., Firestone R.A. Reversal of doxorubicin resistance and catalytic neutralization of lysosomes by a lipophilic imidazole. Biochim. Biophys. Acta. 1191:1994;103-108.
32. Altan N., Chen Y., Schindler M., Simon S.M. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 96:1999;4432-4437.
33. Burke T.G., Sartorelli A.C., Tritton T.R. Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group. Cancer Chemother. Pharmacol. 21:1988;274-280.
34. Demant E.J., Norskov-Lauritsen N. Binding of transferrin-iron by adriamycin at acidic pH. FEBS Lett. 196:1986;321-324.
35. Goda K., Balkay L., Marian T., Tron L., Aszalos A., Szabo G.J. Intracellular pH does not affect drug extrusion by P-glycoprotein. J. Photochem. Photobiol. 34:1996;177-182.
36. Skovsgaard T. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem. Pharmacol. 26:1977;215-222.
37. Gallois L., Fiallo M., Garnier-Suillerot A. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Biochim. Biophys. Acta. 1370:1998;31-40.
38. Frezard F., Pereira-Maia E., Quidu P., Priebe W., Garnier-Suillerot A. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Eur. J. Biochem. 268:2001;1561-1567.
39. Faulds D., Balfour J.A., Chrisp P., Langtry H.D. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 41:1991;400-449.
40. Saletan S. Mitoxantrone: an active, new antitumor agent with an improved therapeutic index. Cancer Treat. Rev. 14:1987;297-303.
41. Pommier Y., Schwartz R.E., Zwelling L.A., Kohn K.W. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry. 24:1985;6406-6410.
42. Jahde E., Glusenkamp K.H., Rajewsky M.F. Protection of cultured malignant cells from mitoxantrone cytotoxicity by low extracellular pH: a possible mechanism for chemoresistance in vivo. Eur. J. Cancer. 26:1990;101-106.
43. Kozin S.V., Shkarin P., Gerweck L.E. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res. 61:2001;4740-4743.
44. Vukovic V., Tannock I.F. Influence of low pH on cytotoxicity of paclitaxel mitoxantrone and topotecan. Br. J. Cancer. 75:1997;1167-1172.
45. Reszka K.J., Chignell C.F. Acid-catalyzed oxidation of the anticancer agent mitoxantrone by nitrite ions. Mol. Pharmacol. 50:1996;1612-1618.
46. Rentsch K.M., Schwendener R.A., Hanseler E. Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography. J. Chromatogr. Biomed. Appl. 679:1996;185-192.
47. Wall M.E., Wani M.C. Camptothecin and taxol: discovery to clinic. Cancer Res. 55:1995;753-760.
48. Schiff P.B., Hortwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U.S.A. 77:1980;1561-1565.
49. Pazdur R., Kudelka A.P., Kavanagh J.J., Cohen P.R., Raber M.N. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat. Rev. 19:1993;351-386.
50. Donato R. Calcium-independent, pH-regulated effects of S-100 proteins on assembly-disassembly of brain microtubule protein in vitro. J. Biol. Chem. 263:1988;106-110.
51. Arnold H., Bourseaux F., Brock N., Asaumi J., Kawasaki S., Nishikawa K., Kuroda M., Hiraki Y. Chemotherapeutic action of cyclic nitrogen mustard phosphamide ester (B518-ASTA) in experimental tumours of the rat. Influence of the extracellular pH. Nature. 181:1958;931-934.
52. Fenselau C., Kan M.N., Rao S.S., Myles A., Friedman O.M., Colvin M. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res. 37:1977;2538-2543.
53. Sladek N.E. Influence of aldehyde dehydrogenase activity on the sensitivity of lymphocytes and other blood cells to oxazaphosphorines. Methods Findings Exp. Clin. Pharmacol. 9:1987;617-626.
54. Jahde E., Glusenkamp K.H., Rajewsky M.F. Increased drug cytotoxicity at reduced pH counteracts cyclophosphamide resistance in cultured rat mammary carcinoma cells. Int. J. Cancer. 44:1989;1082-1087.
55. 31P NMR investigations of phosphoramide mustard: evaluation of pH control over the rate of intramolecular cyclization to an aziridinium ion and the hydrolysis of this reactive alkylator J. Med. Chem. 22:1979;897-899.
56. Balbinder E., Reich C.I., Shugarts D., Keogh J., Fibiger R., Jones T., Banks A. Relative mutagenicity of some urinary metabolites of the antitumor drug cyclophosphamide. Cancer Res. 41:1981;2967-2972.
57. Portlock C.S., Fischer D.S., Cadman E., Lundberg W.B., Levy A., Bobrow S., Bertino J.R., Farber L. High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma. Cancer Treat. Rep. 71:1987;1029-1031.
58. McLean A., Newell D., Baker G., Connors T. The metabolism of chlorambucil. Biochem. Pharmacol. 29:1980;2039-2047.
59. Miyamoto K., Wakabayashi D., Minamino T., Nomura M. Glutathione-S-transferase P-form dependent chlorambucil resistance to Yoshida rat ascites hepatoma cell lines. Cancer Lett. 78:1994;77-83.
60. Jiang B.Z., Bank B.B., Hsiang Y.H., Shen T., Potmesil M., Silber R. Lack of drug-induced DNA cross-links in chlorambucil-resistance Chinese hamster ovary cells. Cancer Res. 49:1989;5514-5517.
61. Mikkelsen R.B., Asher C., Hicks T. Extracellular pH, transmembrane distribution and cytotoxicity of chlorambucil. Biochem. Pharmacol. 34:1985;2531-2534.
62. Skarsgard L.D., Chaplin D.J., Wilson D.J., Skwarchuk M.W., Vinczan A., Kristl J. The effect of hypoxia and low pH on the cytotoxicity of chlorambucil. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;737-741.
63. Kuin A., Aalders M., Lamfers M., van Zuidam D.J., Essers M., Beijnen J.H., Smets L.A. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Br. J. Cancer. 79:1999;793-801.
64. Parkins C.S., Chadwick J.A., Chaplin D.J. Inhibition of intracellular pH control and relationship to cytotoxicity of chlorambucil and vinblastine. Br. J. Cancer Suppl. 27:1996;s75-s77.
65. Jahde E., Glusenkamp K.H., Klunder I., Hulser D.F., Tietze L.F., Rajewsky M.F. Hydrogen ion-mediated enhancement of cytotoxicity of bis-chloroethylating drugs in rat mammary carcinoma cells in vitro. Cancer Res. 49:1989;2965-2972.
66. Pinedo H.M., Peters G.F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6:1988;1653-1664.
67. Peters G.J., Laurensse E., Leyva A., Lankelma J., Pinedo H.M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 46:1986;20-28.
68. Trouet A., Massoulie J., Michelson A.M., Pochon F. Polynucleotide analogues. VI. Physical studies on 5-substituted pyrimidine polynucleotides. Biochim. Biophys. Acta. 114:1966;16-26.
69. Schuetz J.D., Wallace H.J., Diasio R.B. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res. 44:1984;1358-1363.
70. Ojugo A.S., McSheehy P.M., Stubbs M., Alder G., Bashford C.L., Maxwell R.J., Leach M.O., Judson I.R., Griffiths J.R. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br. J. Cancer. 77:1998;873-879.
71. McSheehy P.M., Robinson S.P., Ojugo A.S., Aboagye E.O., Cannell M.B., Leach M.O., Judson I.R., Griffiths J.R. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res. 58:1998;1185-1194.
72. Raghunand N., He X., van Sluis R., Mahoney B., Baggett B., Taylor C.W., Paine-Murrieta G., Roe D., Bhujwalla Z.M., Gillies R.J. Enhancement of chemotherapy by manipulation of tumour pH. Br. J. Cancer. 80:1999;1005-1011.
73. Gillies R.J., Didier N., Denton M. Determination of cell number in monolayer cultures. Anal. Biochem. 159:1986;109-113.
74. McSheehy P.M., Stubbs M., Griffiths J.R. Role of pH in tumor-trapping of the anticancer drug 5-fluorouracil. Adv. Enzyme Regul. 40:2000;63-80.
75. 31P MRS Neoplasia. 4:2002;539-543.